Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Shareholders' Deficit (Unaudited)

v3.20.2
Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($)
Common Stock
Additional Paid-In Capital
Retained Earnings (deficits)
Total
Beginning balance, shares at Dec. 31, 2018 25,229,833      
Beginning balance, value at Dec. 31, 2018 $ 25,230 $ 4,688,272 $ (8,540,053) $ (3,826,551)
Stock Based Compensation   588,697   588,697
Stock Options Issued for loan term revisions, value   17,827   17,827
Stock grant program vesting, shares 20,000      
Stock grant program vesting, value $ 20 (20)    
Warrants issued related to debt   101,741   101,741
Stock issuance related to acquisition, shares 500,000      
Stock issuance related to acquisition, value $ 500 999,500   100,000
Equity value of exercise price associated with convertible debentures   119,212   119,212
Net loss     (1,481,471) (1,481,471)
Ending balance, shares at Mar. 31, 2019 25,749,833      
Ending balance, value at Mar. 31, 2019 $ 25,750 6,515,229 (10,021,524) (3,480,545)
Beginning balance, shares at Dec. 31, 2018 25,229,833      
Beginning balance, value at Dec. 31, 2018 $ 25,230 4,688,272 (8,540,053) (3,826,551)
Ending balance, shares at Dec. 31, 2019 28,209,312      
Ending balance, value at Dec. 31, 2019 $ 28,209 11,854,083 (16,890,626) (5,008,334)
Clawback of stock granted, shares (100,000)      
Clawback of stock granted, value $ (100) 100    
Stock Options Issued for loan term revisions, shares 100,000      
Stock Options Issued for loan term revisions, value $ 100 99,900   100,000
Warrants issued related to debt   76,822   76,822
Stock issuance related to debt, shares 500,000      
Stock issuance related to debt, value $ 500 499,500   500,000
Net loss     (1,695,631) (1,695,631)
Ending balance, shares at Mar. 31, 2020 28,709,312      
Ending balance, value at Mar. 31, 2020 $ 28,709 $ 12,963,050 $ (18,586,257) $ (5,594,498)